A colon cancer blood test looks for cancer that is already there. A colonoscopy looks for the polyps that turn into cancer and takes them out while you are asleep. In the guides we publish here, that difference is the one that decides this comparison, and it is the one most coverage of the new blood tests leaves until last.
Both tests are legitimate screening options and the US Food and Drug Administration approved Guardant Health's Shield in July 2024 as a primary screening choice for average-risk adults aged 45 and over. They are not two versions of the same test.
The Verdict
What Each Test Is Designed to Do
Shield is a diagnostic test in the strict sense. It reads circulating tumour DNA in a blood sample and reports whether a signal consistent with colorectal cancer is present. It reports on a state of affairs.
Colonoscopy is a procedure that is diagnostic and therapeutic at once. A camera goes through the colon, the gastroenterologist looks at the lining directly, and anything suspicious is removed while they are in there. Most colorectal cancers develop from adenomatous polyps over a period of years, so removing one is not an early treatment for cancer. It is the prevention of a cancer that never happens.
That distinction is why the two tests cannot be ranked on a single accuracy figure. They are answering different questions.
The Numbers Side by Side
Nine dimensions separate them, and the blood test wins on four of them.
| Shield blood test | Colonoscopy | |
|---|---|---|
| What it detects | Tumour DNA circulating in blood from a colorectal cancer already present | Cancer and precancerous polyps, seen directly through a camera |
| Sensitivity for colorectal cancer | About 83 percent in the ECLIPSE registrational study | Around 95 percent |
| Sensitivity for advanced precancerous lesions | About 13 percent | Around 90 percent, and it removes them in the same session |
| Can it prevent cancer? | No. It reports on cancer that already exists | Yes. Removing an adenoma stops it becoming a cancer |
| Preparation | None. A routine blood draw | A full bowel preparation the day before, and a day off work |
| Sedation and recovery | None | Sedation in most US practice, plus someone to drive you home |
| Procedural risk | The risk of a blood draw | Perforation and bleeding are uncommon and real, in the range of 1 in 1,000 to 1 in 3,000 for perforation |
| Screening interval | Every three years for qualifying blood-based tests under Medicare rules | Every ten years after a normal result with no polyps found |
| What a positive result triggers | A diagnostic colonoscopy | Nothing further. The colonoscopy already answered the question |
Rows two and three are the pair to read together. On cancer detection the two tests are within about twelve percentage points of each other. On advanced precancerous lesions they are not close, and it is not a small gap in a secondary measure. It is the difference between a test that finds disease and a procedure that prevents it.
Rows five through seven are where the blood test wins, and those wins are the reason it exists. No bowel preparation, no sedation, no day off work, and no procedural risk beyond a needle.
Why Precancerous Polyps Are the Whole Argument
Colorectal cancer is unusual among common cancers in having a long, visible, removable precursor. An adenomatous polyp can sit in the colon for years before any of its cells become malignant, and taking it out during a routine colonoscopy ends the sequence.
This is why colonoscopy-based screening reduces colorectal cancer incidence rather than only catching it earlier. Programmes built around it lower the number of cancers that occur, which is a stronger claim than lowering the number that are found late.
Shield's roughly 13 percent detection of advanced precancerous lesions means it will miss the great majority of them. The reason is biological rather than technical: a benign polyp is not invading tissue and is not shedding much DNA into the bloodstream, so there is very little signal for the assay to find. Better software will not solve that.
What the Blood Test Route Involves
The practical experience is a standard venous blood draw at a laboratory or a physician's office, with a result returned in a couple of weeks. There is no dietary restriction, no collection kit and nothing to post.
Three things are worth knowing before choosing it.
- The interval is three years rather than ten. Under Medicare rules for qualifying blood-based screening tests, repetition is every three years, which reflects the lower single-test sensitivity.
- A prescription is required. It is an ordered test rather than a direct-to-consumer kit, so it runs through a clinician.
- The follow-up colonoscopy is billed separately. Coverage of a colonoscopy performed after a positive non-invasive screening test has been a recurring billing dispute in the US, and it is worth confirming with your plan rather than assuming.
Our page on cancer screening blood test accuracy covers how to read the sensitivity and specificity figures in this category, including what a positive result is likely to mean in your own risk group.
What Colonoscopy Involves
The procedure itself is straightforward and the preparation is what people object to. A day of clear liquids and a bowel preparation solution the evening before, sedation on the day, and somebody to take you home afterwards.
Risk is low and not zero. Perforation occurs in roughly 1 in 1,000 to 1 in 3,000 screening colonoscopies, and post-polypectomy bleeding is somewhat more common. Both are more likely in older patients and where extensive polyp removal is performed.
Against that, a normal result with no polyps found buys ten years. Over a screening life running from 45 to 75, that is three procedures. The same period on the blood test is ten draws, and any positive among them adds a colonoscopy on top.
Where Stool Tests Sit Between Them
The choice is not binary, and the stool-based options occupy the middle of this range on both accuracy and convenience.
| Test | Interval | Sensitivity | Where it wins | Where it costs you |
|---|---|---|---|---|
| Shield blood test | Every 3 years | About 83 percent for cancer, about 13 percent for advanced precancerous lesions | Nothing to collect at home, nothing to prepare | A positive result still requires a colonoscopy |
| FIT stool test | Annually | Roughly 74 percent for cancer, and low for advanced adenomas | Cheapest option, done at home, no prep | It works through annual repetition, and adherence falls off after the first year |
| Cologuard stool DNA test | Every 3 years | Around 92 percent for cancer and about 42 percent for advanced adenomas in its registrational trial | Higher polyp detection than blood or FIT, still done at home | Higher false positive rate than FIT, which means more diagnostic colonoscopies |
| Colonoscopy | Every 10 years if normal | Around 95 percent for cancer, around 90 percent for advanced adenomas | Finds and removes lesions in one session | Prep, sedation, a day lost, and a small procedural risk |
Exact Sciences' Cologuard detects more advanced adenomas than either the blood test or a FIT test, which makes it the strongest non-invasive option on the prevention side. FIT is the cheapest and depends on being repeated every year, which is where real-world adherence usually breaks down.
The blood test's advantage over both is that nothing has to be collected at home. That sounds trivial written down, and it is the single largest determinant of whether some people get screened at all.
Who Should Choose Which
Four situations cover most readers.
- Anyone at above-average risk should have a colonoscopy. A family history of colorectal cancer, inflammatory bowel disease, a previous adenoma or a genetic syndrome all put you outside the average-risk population these blood tests were approved for.
- Anyone willing to have a colonoscopy should have one. The prevention advantage is large, and ten years between procedures is the least demanding schedule in the whole comparison.
- Anyone who has repeatedly declined screening should take the blood test. The relevant comparison for this group is against nothing, and a test that catches four in five cancers is a considerable improvement on that.
- Anyone who cannot safely undergo sedation or bowel preparation. Frailty, severe cardiorespiratory disease and anticoagulation all complicate colonoscopy, and a non-invasive route is a reasonable answer.
This comparison does not serve anyone under 45 with no symptoms and no family history, where screening is not recommended at all, and it does not serve anyone with current symptoms such as rectal bleeding or a change in bowel habit. Symptoms warrant a diagnostic investigation rather than a screening test, and choosing a blood test in that situation risks a false reassurance that delays the right pathway.
Our reading would change if a next-generation blood assay reached advanced adenoma detection above roughly 40 percent, which is where Cologuard sits. At that point the blood test would be competing on prevention rather than only on detection, and the convenience advantage would start to outweigh the gap. Nothing currently approved is close to that.
Work out which of the four situations above describes you, then book the corresponding test rather than deferring the colon cancer screening decision for another year.
Frequently Asked Questions
Is a colon cancer blood test as good as a colonoscopy?
For finding a cancer that already exists, it is close: Shield reports about 83 percent sensitivity against roughly 95 percent for colonoscopy. For preventing cancer, it is not comparable. Colonoscopy finds and removes advanced precancerous polyps in the same session, and Shield detects about 13 percent of them. Screening programmes reduce colorectal cancer deaths partly by removing polyps before they turn into cancer, and a blood test cannot do that job at all.
Is the Shield blood test FDA approved?
Yes. The FDA approved Guardant Health's Shield test in July 2024 as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. It was the first blood test approved in that role. The approval rested on the ECLIPSE study, which enrolled more than 20,000 average-risk adults across more than 200 sites in 37 states, and the results were published in the New England Journal of Medicine.
Does Medicare cover a colon cancer blood test?
Medicare covers blood-based colorectal cancer screening tests that meet defined criteria, at an interval of every three years, for beneficiaries in the eligible age range. Coverage for commercial plans varies and has been expanding since the FDA approval. Because coverage rules and intervals change, confirm the current position with your plan and with the test provider before assuming a price. A follow-up colonoscopy after a positive result is billed separately.
What happens if the blood test is positive?
A positive Shield result means a diagnostic colonoscopy, and that is the entire pathway. The blood test is a triage step that decides whether you need the procedure, so a positive result puts you exactly where you would have been if you had chosen colonoscopy first, with a delay attached. This is the single most important thing to understand before choosing the blood test route: it does not remove the possibility of a colonoscopy, it defers it.
Why does the blood test miss precancerous polyps?
Advanced adenomas are not cancer, and they shed very little material into the bloodstream. Circulating tumour DNA assays look for genetic and methylation signals from cells that are actively dividing, invading and shedding, which is a description of a cancer rather than of a benign polyp. The 13 percent figure is a limit of the underlying biology rather than a gap this generation of assays will close with better software.
Is a blood test better than a stool test for colon cancer?
Cologuard detects more advanced adenomas than either the blood test or a FIT test, at around 42 percent in its registrational trial, which makes it the stronger non-invasive option on the prevention side. FIT is the cheapest and needs repeating annually to work. The blood test wins on one axis only, which is that nothing has to be collected at home. For people who will not do a stool test, that axis matters more than the accuracy comparison suggests.
How often do you need the Shield blood test?
Every three years under the Medicare interval for qualifying blood-based tests, compared with ten years for a normal colonoscopy and one year for FIT. The shorter interval reflects lower single-test sensitivity: repeating a less sensitive test more often recovers some of the detection you lose per round. Over a 30-year screening life that is ten blood draws against three colonoscopies, which changes the total cost comparison more than a single-test price does.
When should colon cancer screening start?
The US Preventive Services Task Force recommends screening for colorectal cancer starting at age 45 for average-risk adults, and continuing to 75, with the decision between 76 and 85 made individually. The age was lowered from 50 in 2021 in response to rising incidence in younger adults. Anyone with a family history of colorectal cancer, inflammatory bowel disease or a genetic syndrome is not average risk and should be on a colonoscopy-based schedule set by a gastroenterologist.
Related
- Cancer screening blood test accuracy: how to read the figures
- Best multi-cancer blood test: the multi-cancer options compared
- Galleri review: the multi-cancer test in detail
- Colorectal screening mortality evidence: what the trials show
- Full body MRI: the imaging route to whole-body screening
- At-home blood test accuracy: the collection question